stockrow
Saturday 7 November 2026
Export PGEN’s income statement to Excel — free account
Precigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024.
- Revenue
- +2,437.6%
- EPS
- +109.4%
- Free cash flow
- +140.3%
- Total debt
- +1.47%
Quarter to September 2026, against a year earlier
4.43
0.21
+4.98%
Follow PGEN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(1,446.02%) | (12,417.99%) | (9,907.46%) | 38.84% | |
Piotroski F-Score |
3 | 4 | 4 | 6 | |
| (285.69%) | (286.76%) | (247.40%) | 12.73% | ||
ROIC |
(425.63%) | (102.06%) | (24.87%) | 15.93% | |
Return on Tangible Assets |
(468.60%) | (408.82%) | (285.75%) | 15.82% | |
Average Days of Receivables |
164.41 | 308.51 | 306.78 | 224.71 | |
Free Cash Flow per Share |
(0.29) | (0.33) | (0.32) | (0.21) | |
Free Cash Flow |
(89.83) | (116.96) | (115.22) | (74.32) | |
Capital Expenditures |
(1.99) | (1.63) | (1.06) | (1.10) | |
| Other line items | |||||
Cash ROIC |
(42.38%) | (68.80%) | (65.59%) | (33.16%) | |
Accounts Receivable Turnover |
3.51 | 2.28 | 2.36 | 3.21 | |
Accounts Payable Turnover |
0.62 | 2.21 | 1.73 | 2.02 | |
Inventory Turnover |
0.98 | 0.84 | 0.78 | 1.04 | |
Average Days of Payables |
907.01 | 150.43 | 242.15 | 191.23 | |
Days of Inventory on Hand |
725.08 | 855.56 | 924.26 | 621.03 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
426.82% | 115.50% | 37.67% | 16.91% | |
Selling, General and Administrative Expense of Revenue |
724.16% | 249.46% | 99.09% | 53.08% | |
Share Based Compensation of Revenue |
117.65% | 37.10% | 15.94% | 8.32% | |
Interest Coverage |
(28.58) | (13.86) | (4.06) | 2.85 | |
Operating CF/Net income |
0.20 | 0.30 | 0.34 | (3.00) | |
Depreciation/Fixed assets |
0.38 | 0.48 | 0.28 | 0.33 | |
Capex/Depreciation |
(0.38) | (0.25) | (0.29) | (0.25) | |
Revenue per Share |
0.03 | 0.09 | 0.24 | 0.44 | |
Operating CF per Share |
(0.28) | (0.33) | (0.32) | (0.20) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.21 | 0.05 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 6 Nov 2026